1. Coumel P., Fidelle J., Lucet V., et al. Catecholamine-induced severe ventricular arrhythmias with Adams-Stokes syndrome in children: report of four cases. // Br Heart J. - 1978; 40 (suppl): P. 28-37.
2. Priori S.G., Napolitano C., Tiso N., et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. // Circulation 2001 (103). - P. 196-200.
3. Leenhardt A., Lucet V., Denjoy I., et al. Catecholaminergic polymorphic ventricular tachycardia in children: a 7-year follow-up of 21 patients. // Circulation. 1995 (91). -P.1512-1519.
4. Swan H., Piippo K., Viitasalo M., et al. Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts. // J Am Coll Cardiol. - 1999 (34). - P. 2035-2042.
5. Priori S.G., Napolitano C., Memmi M., et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. // Circulation. -2002 (106). - P. 69-74.
6. Lahat H., Eldar M., Levy-Nissenbaum E., et al. Autosomal recessive catecholamine- or exercise-induced polymorphic ventricular tachycardia: Clinical features and assignment of the disease gene to chromosome 1p13-21. // Circulation. - 2001 (103). - P. 2822-2827.
7. Kalscheur M.M., Vaidyanathan R., Orland K.M., et al. KCNJ2 mutation causes an adrenergic-dependent rectification abnormality with calcium sensitivity and ventricular arrhythmia. // Heart Rhythm. - 2014; 11(5). - P. 885-94.
8. Roux-Buisson N., Cacheux M., Fourest-Lieuvin A., et al. Absence of triadin, a protein of the calcium release complex, is responsible for cardiac arrhythmia with sudden death in human. // Hum. Molec. Genet. - 2012 (21). - P. 2759-2767, 2012.
9. HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes // Heart Rhythm. - 2013. - Vol 10. - P. 1932-1963.
10. Tester D.J., Spoon D.B., Valdivia H.H., et al. Targeted mutational analysis of the RyR2-encoded cardiac ryanodine receptor in sudden unexplained death: a molecular autopsy of 49 medical examiner/coroner’s cases. // Mayo Clin Proc. - 2004 (79). - P. 1380 -1384.
11. Sumitomo N., Harada K., Nagashima M., et al. Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. // Heart. - 2003 (89). - P. 66 -70.
12. Hayashi M., Denjoy I., Extramiana F., et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. // Circulation. - 2009 (119). - P. 2426-2434.
13. Watanabe H., Chopra N., Laver D., et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. // Nat Med. - 2009 (15). - P. 380-383.
14. Odero A., Bozzani A., De Ferrari G.M., Schwartz P.J. Left cardiac sympathetic denervation for the prevention of life-threatening arrhythmias: the surgical supraclavicular approach to cervicothoracic sympathectomy. // Heart Rhythm. - 2010 (7). - P. 1161-1165.
15. De Ferrari G.M, Dusi V., Spazzolini C., et al. Clinical management of catecholaminergic polymorphic ventricular tachycardia the role of left cardiac sympathetic denervation. // Circulation. - 2015 (131). - P. 2185-2193.